Compare Ascendis Pharma A/S (ASND) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs United Microelectronics Corp — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while United Microelectronics Corp trades at $23.66 (market cap $61.20B). The key difference: United Microelectronics Corp is far larger — about 3.4× Ascendis Pharma A/S's market cap, and United Microelectronics Corp pays a 1.69% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | UMC | |
|---|---|---|
Market Cap | $17.74B | $61.20B |
Sector | Health | Technology |
52-Week High | $277.18 | $28.02 |
52-Week Low | $163.32 | $6.58 |
Enterprise Value | $18.11B | $58.77B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
UMC trades at $24.34, down 2.09% today, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $237.55B in 2025, though net income margin compressed to 16.99%. Recent June 2026 sales rose 22.85% year-over-year, and the company launched a 14nm eHV FinFET platform for display drivers. Analyst consensus is mixed with 27% buy ratings, while institutional sentiment leans positive amid AI and automotive chip demand.
Outlook: UMC benefits from specialty semiconductor demand, but high P/E of 39.52 and margin pressures pose valuation risks. Earnings beats and dividend payments support income investors, yet competition and cyclical industry volatility require caution for growth-focused shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
